Pestalozzi advises The European Investment Bank on financing agreement with BioVersys

The European Investment Bank (EIB), the lending arm of the European Union, and BioVersys, a privately-owned clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, announced the signing of a EUR 20 million venture debt transaction.

The financing supports the company’s research and development of a diverse pipeline of drugs that address antimicrobial resistance (AMR). AMR causes the majority of antimicrobial therapies to become obsolete. Due to its potential to trigger a new bacterial pandemic, AMR has been widely recognised as the top priority health threat by the WHO, G7 and G20.

Pestalozzi advised EIB on all Swiss law aspects of this transaction with a team that included
Franz Schubiger (Partner – Corporate / M&A, Life Sciences – pictured), Nils Harbeke (Partner – Tax), Urs Kloeti (Partner – Financial Services), Daniela Fritsch (Associate – Financial Services), Severin Etzensperger (Associate – IP & TMT, Life Sciences)

Pestalozzi advises The European Investment Bank on financing agreement with BioVersys


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram